Goldman Sachs Group set a €74.50 ($88.69) price objective on Fresenius SE & Co. KGaA (FRA:FRE) in a research note published on Tuesday, November 14th. The brokerage currently has a neutral rating on the stock.
A number of other equities analysts have also recently issued reports on the company. Berenberg Bank set a €89.10 ($106.07) price objective on Fresenius SE & Co. KGaA and gave the company a buy rating in a report on Tuesday, November 14th. DZ Bank reiterated a buy rating on shares of Fresenius SE & Co. KGaA in a report on Monday, November 13th. Commerzbank set a €85.00 ($101.19) target price on Fresenius SE & Co. KGaA and gave the stock a buy rating in a report on Monday, November 6th. S&P Global set a €85.00 ($101.19) target price on Fresenius SE & Co. KGaA and gave the stock a buy rating in a report on Monday, November 6th. Finally, Bank of America set a €75.00 ($89.29) target price on Fresenius SE & Co. KGaA and gave the stock a neutral rating in a report on Monday, November 6th. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of €79.48 ($94.61).
Shares of Fresenius SE & Co. KGaA (FRA FRE) traded up €0.16 ($0.19) during trading on Tuesday, hitting €61.03 ($72.65). The stock had a trading volume of 4,288 shares. Fresenius SE & Co. KGaA has a 12-month low of €60.16 ($71.62) and a 12-month high of €80.00 ($95.24).
ILLEGAL ACTIVITY NOTICE: “Fresenius SE & Co. KGaA (FRA:FRE) Given a €74.50 Price Target by Goldman Sachs Group Analysts” was posted by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://baseballnewssource.com/markets/goldman-sachs-group-inc-the-reiterates-74-50-price-target-for-fresenius-se-co-kgaa-fre/1782234.html.
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with our FREE daily email newsletter.